Anzeige
Mehr »
Login
Samstag, 11.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
1.965 Leser
Artikel bewerten:
(0)

Alkermes Announces Departure of Jim Robinson

DUBLIN, April 8, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that Jim Robinson, President and Chief Operating Officer, has resigned from his position and will leave the company, effective April 19, 2019, for personal reasons.

"The past year has been incredibly rewarding and I am honored to have had the opportunity to work for an organization so committed to making an impact for patients struggling with serious mental illness and addiction," said Jim Robinson. "This was an exceedingly difficult decision, but after much reflection, it is the right choice for me and my family. I have tremendous admiration and respect for the employees of Alkermes and look forward to watching their future progress."

"On behalf of the Alkermes team, I would like to thank Jim for his contributions, and I wish him well in his future endeavors," said Richard Pops, Chief Executive Officer. "Alkermes is rooted in our mission to bring patient-centered treatment options to those suffering from serious CNS disorders. We have assembled a diverse and important collection of capabilities and expertise and we are well positioned to further build our leadership position in these challenging disease areas."

About Alkermes plc
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and oncology. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contacts:
For Investors: Sandy Coombs, +1 781 609 6377
For Media: Matthew Henson, +1 781 609 6637

Alkermes plc Logo

Logo - https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg

Lithium vs. Palladium - Ist das die Chance des Jahrzehnts?
Sichern Sie sich den kostenlosen PDF-Report! So können Sie vom Boom der Rohstoffe profitieren.
Hier klicken
© 2019 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.